These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 22019804)

  • 1. Comparison of recommendations for the use of anti-tumour necrosis factor therapy in ankylosing spondylitis in 23 countries worldwide.
    van den Berg R; Stanislawska-Biernat E; van der Heijde DM
    Rheumatology (Oxford); 2011 Dec; 50(12):2270-7. PubMed ID: 22019804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis.
    Braun J; Davis J; Dougados M; Sieper J; van der Linden S; van der Heijde D;
    Ann Rheum Dis; 2006 Mar; 65(3):316-20. PubMed ID: 16096329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis.
    van der Heijde D; Sieper J; Maksymowych WP; Dougados M; Burgos-Vargas R; Landewé R; Rudwaleit M; Braun J;
    Ann Rheum Dis; 2011 Jun; 70(6):905-8. PubMed ID: 21540200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment guidelines for ankylosing spondylitis and its effect on Mexican rheumatology].
    Burgos-Vargas R; Abud-Mendoza C; Díaz-Jouanen E; Garza-Elizondo MA; Medrano-Ramírez G; Orozco-Alcalá J; Pacheco-Tena C; Pineda-Villaseñor C; Carlos-Pozos J; Ramos-Niembro F; Robles-San Román M; Santana-Sahagún E
    Gac Med Mex; 2009; 145(1):41-9. PubMed ID: 19256410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis.
    Baraliakos X; van den Berg R; Braun J; van der Heijde D
    Rheumatology (Oxford); 2012 Aug; 51(8):1378-87. PubMed ID: 22427410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis.
    Braun J; Pham T; Sieper J; Davis J; van der Linden S; Dougados M; van der Heijde D;
    Ann Rheum Dis; 2003 Sep; 62(9):817-24. PubMed ID: 12922952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ASAS/EULAR recommendations for the management of ankylosing spondylitis: the patient version.
    Kiltz U; van der Heijde D; Mielants H; Feldtkeller E; Braun J;
    Ann Rheum Dis; 2009 Sep; 68(9):1381-6. PubMed ID: 18930993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anti-TNF alfa therapy in ankylosing spondylitis].
    Cravo AR; Tavares V; Da Silva JC
    Acta Med Port; 2006; 19(2):141-50. PubMed ID: 17187716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [ASAS recommendations on the use of TNF inhibitors for patients with axial spondyloarthritis : evaluation of the 2010 update in the German-speaking area].
    Kiltz U; Sieper J; Braun J
    Z Rheumatol; 2013 Feb; 72(1):81-8. PubMed ID: 23338704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and treatment responses of patients satisfying the BSR guidelines for anti-TNF in ankylosing spondylitis.
    Gadsby K; Deighton C
    Rheumatology (Oxford); 2007 Mar; 46(3):439-41. PubMed ID: 17255137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The percentage of patients with seronegative spondyloarthritis requiring magnetic resonance imaging to meet the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada guidelines for access to anti-tumor necrosis factor treatment.
    Troppmann L; Karsh J;
    J Rheumatol; 2008 Apr; 35(4):658-61. PubMed ID: 18278833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial.
    Song IH; Heldmann F; Rudwaleit M; Listing J; Appel H; Braun J; Sieper J
    Arthritis Rheum; 2010 May; 62(5):1290-7. PubMed ID: 20461780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experts' beliefs on physiotherapy for patients with ankylosing spondylitis and assessment of their knowledge on published evidence in the field. Results of a questionnaire among international ASAS members.
    Mihai B; van der Linden S; de Bie R; Stucki G
    Eura Medicophys; 2005 Jun; 41(2):149-53. PubMed ID: 16200031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ASAS/EULAR recommendations for the management of ankylosing spondylitis.
    Zochling J; van der Heijde D; Burgos-Vargas R; Collantes E; Davis JC; Dijkmans B; Dougados M; Géher P; Inman RD; Khan MA; Kvien TK; Leirisalo-Repo M; Olivieri I; Pavelka K; Sieper J; Stucki G; Sturrock RD; van der Linden S; Wendling D; Böhm H; van Royen BJ; Braun J; ;
    Ann Rheum Dis; 2006 Apr; 65(4):442-52. PubMed ID: 16126791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab.
    Baraliakos X; Listing J; Brandt J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Rudwaleit M; Sieper J; Braun J
    Arthritis Res Ther; 2005; 7(3):R439-44. PubMed ID: 15899030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis.
    Maksymowych WP; Inman RD; Gladman D; Thomson G; Stone M; Karsh J; Russell AS;
    J Rheumatol; 2003 Jun; 30(6):1356-63. PubMed ID: 12784417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessments in ankylosing spondylitis.
    Zochling J; Braun J
    Best Pract Res Clin Rheumatol; 2007 Aug; 21(4):699-712. PubMed ID: 17678831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.
    Barkham N; Kong KO; Tennant A; Fraser A; Hensor E; Keenan AM; Emery P
    Rheumatology (Oxford); 2005 Oct; 44(10):1277-81. PubMed ID: 16105913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editorial review: how early should ankylosing spondylitis be treated with a tumor necrosis factor-blocker?
    Haibel H; Sieper J
    Curr Opin Rheumatol; 2010 Jul; 22(4):388-92. PubMed ID: 20473176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of ankylosing spondylitis and undifferentiated spondyloarthritis with TNF alpha-antagonists].
    Brandt J; Sieper J; Braun J
    Z Rheumatol; 2003 Jun; 62(3):218-27. PubMed ID: 12827397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.